ReviewBiomarkers in cancer2016
Predicting Clinical Outcomes Using Molecular Biomarkers.
Review in Biomarkers in cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Transformative Role of Artificial Intelligence in Drug Discovery and Translational Medicine: Innovations, Challenges, and Future Prospects.Drug design, development and therapy · 2025Pooled it
- Identification of Candidate Biomarkers for Transplant Rejection from Transcriptome Data: A Systematic Review.Molecular diagnosis & therapy · 2019Pooled it
- MCVAE-based multi-omic anomaly detection in Fragile X Syndrome.NAR molecular medicine · 2026Article
- Review of Existing Approaches and Potential Role of Pharmacometrics in the Interpretation of Prognostic Circulating Serum Biomarkers in Advanced NSCLC.Clinical and translational science · 2026Review
- Production of a risk mitigation matrix and four-grade threshold scale using Cox Regression to predict osteoarthritis development.Open life sciences · 2026Article
- Clinicopathological Significance of Pluripotent Factors in Sinonasal Intestinal-Type Adenocarcinoma.Cancers · 2025Article
- Identification of diagnostic microRNAs and their target genes in multiple sclerosis based on interactome networks using an in silico approach.Current journal of neurology · 2025Article
- Exploring the complex relationship between metabolomics and breast cancer early detection (Review).Molecular and clinical oncology · 2025Review
- In silico prediction of differentially expressed genes and functionally grouped networks in patients with inflamed pulp for screening pulpitis biomarkers.European oral research · 2025Article
- Conceptual basis for the development of guidance for the use of biomarkers of effect in regulatory risk assessment of chemicals.EFSA journal. European Food Safety Authority · 2024Article
- Copeptin: a novel prognostic biomarker in trauma: a review article.Journal of health, population, and nutrition · 2023Review
- Severe Acute Bronchial Asthma with Sepsis: Determining the Status of Biomarkers in the Diagnosis of the Disease.Diagnostics (Basel, Switzerland) · 2023Review
- Review
- Plasma bioactive adrenomedullin predicts outcome after acute stroke in early rehabilitation.Scientific reports · 2023Observational
- Preventable risk factors for type 2 diabetes can be detected using noninvasive spontaneous electroretinogram signals.PloS one · 2023Article
- Mass Spectrometry-Based Proteomics of Human Milk to Identify Differentially Expressed Proteins in Women with Breast Cancer versus Controls.Proteomes · 2022Article
- Severe testing with high-dimensional omics data for enhancing biomedical scientific discovery.NPJ systems biology and applications · 2022Article
- Complete response to sotorasib as neoadjuvant treatment in patient with locally advanced primary pulmonary sarcoma harboringAnnals of translational medicine · 2022Article
- Rational Approach to Finding Genes Encoding Molecular Biomarkers: Focus on Breast Cancer.Genes · 2022Article
- It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer.Life (Basel, Switzerland) · 2022Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past 20 years, there has been an exponential increase in the number of biomarkers. At the last count, there were 768,259 papers indexed in PubMed.gov directly related to biomarkers. Although many of these papers claim to report clinically useful molecular biomarkers, embarrassingly few are currently in clinical use. It is suggested that a failure to properly understand, clinically assess, and utilize molecular biomarkers has prevented their widespread adoption in treatment, in comparative benefit analyses, and their integration into individualized patient outcome predictions for clinical decision-making and therapy. A straightforward, general approach to understanding how to predict clinical outcomes using risk, diagnostic, and prognostic molecular biomarkers is presented. In the future, molecular biomarkers will drive advances in risk, diagnosis, and prognosis, they will be the targets of powerful molecular therapies, and they will individualize and optimize therapy. Furthermore, clinical predictions based on molecular biomarkers will be displayed on the clinician's screen during the physician-patient interaction, they will be an integral part of physician-patient-shared decision-making, and they will improve clinical care and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.